Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis

scientific article published on 01 February 1995

Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/AJH.2830480208
P698PubMed publication ID7847323

P2093author name stringJ M Rowe
J F DiPersio
N Blumberg
J M Heal
S A Kirkley
A P Rapoport
P433issue2
P304page(s)108-115
P577publication date1995-02-01
P1433published inAmerican Journal of HematologyQ4744246
P1476titleLeukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis
P478volume48

Reverse relations

cites work (P2860)
Q35938500Clinical and economic impact of epoetins in cancer care
Q34913728Inline-filtration
Q35924467Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products
Q33835138Leukocyte reduction of blood components: public policy and new technology
Q33361167Optimizing platelet transfusion therapy
Q45258025Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery
Q50600606The role and impact of the transfusion medicine consultation service in the management of patients in the hematopoietic transplant service: A retrospective analysis.
Q53535347The second century of ABO: and now for something completely different.
Q40945066Transfusion and stem cell support in cancer treatment
Q36207276What would Karl Landsteiner do? The ABO blood group and stem cell transplantation
Q33581238When less is more: cost-containment in transfusion medicine

Search more.